Hyperandrogenemia in women with polycystic ovary syndrome: prevalence, characteristics and association with body mass index
-
Eleni Alexiou
,
Charalampos Chrelias
Abstract
Background:
Hyperandrogenemia is one of the major diagnostic features for the diagnosis of polycystic ovary syndrome (PCOS). The aim of this study was to estimate the prevalence and the characteristics of hyperandrogenemia in women with PCOS and to investigate the association of clinical and biochemical characteristics with body mass index (BMI) according to the presence of hyperandrogenemia.
Materials and methods:
We studied 266 women diagnosed with PCOS. Hyperandrogenemia was defined by testosterone (T) and/or free testosterone (FT) and/or ∆4 androstenedione (Δ4-A) higher than 75% of the upper limits of each hormone. Patients were stratified in two groups according to a BMI threshold of 25 kg/m2.
Results:
Hyperandrogenemia was present in 78.2% of the patients. Elevated levels of T were found in 58.4%, while elevated levels of FT and Δ4-A were found in 42.5% and 34.1% of patients. In normal weight women (BMI≤25 kg/m2) with hyperandrogenemia lower values of hip circumference and HOMA-IR and increased levels of T, FT, Δ4-A, 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate (DHEAS), white blood cells (WBC) and neutrophils were observed compared to women without hyperandrogenemia. Also, in overweight women higher levels of T, FT, Δ4-A, 17-OHP, DHEAS and cortisol were measured, while lower thyroid-stimulating hormone (TSH) levels were comparable to women without hyperandrogenemia.
Conclusion:
This study showed high prevalence of hyperandrogenemia in PCOS women. Women with BMI≤25 kg/m2 have significant differences in androgens, WBC, neutrophils and HOMA-IR and women with BMI≥25 kg/m2 in androgens, TSH and cortisol according to the presence or not of hyperandrogenemia.
Author Statement
Funding: Authors state no funding involved.
Conflict of interest: Authors state no conflict of interest.
Informed consent: Informed consent has been obtained from all individuals included in this study.
Ethical approval: The research related to human use complied with all the relevant national regulations, institutional policies and was performed in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.
References
1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016;31:2841–55.10.1093/humrep/dew218Search in Google Scholar PubMed
2. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A, Hougaard DM, Nyboe Andersen A. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 2014;29:791–801.10.1093/humrep/det469Search in Google Scholar PubMed
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7.10.1093/humrep/deh098Search in Google Scholar PubMed
4. Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, Ehrmann DA. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 2011;26:3138–46.10.1093/humrep/der291Search in Google Scholar PubMed PubMed Central
5. Powell BL, Haddad L, Bennett A, Gharani N, Sovio U, Groves CJ, Rush K, Goh MJ, Conway GS, Ruokonen A, Martikainen H, Pouta A, Taponen S, Hartikainen AL, Halford S, Zeggini E, Jarvelin MR, Franks S, McCarthy MI. Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab 2005;90:2988–93.10.1210/jc.2004-2485Search in Google Scholar PubMed
6. Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: investigations and management. Best Pract Res Clin Obstet Gynaecol 2016;37:98–118.10.1016/j.bpobgyn.2016.05.003Search in Google Scholar PubMed
7. Livadas S, Diamanti-Kandarakis E. Polycystic ovary syndrome: definitions, phenotypes and diagnostic approach. Front Horm Res 2013;40:1–21.10.1159/000341673Search in Google Scholar PubMed
8. Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril 2010;93:1938–41.10.1016/j.fertnstert.2008.12.138Search in Google Scholar PubMed PubMed Central
9. Livadas S, Pappas C, Karachalios A, Marinakis E, Tolia N, Drakou M, Kaldrymides P, Panidis D, Diamanti-Kandarakis E. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine 2014;47:631–8.10.1007/s12020-014-0200-7Search in Google Scholar PubMed
10. Barth JH, Field HP, Yasmin E, Balen AH. Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. Eur J Endocrinol 2010;162:611–5.10.1530/EJE-09-0741Search in Google Scholar PubMed
11. Cho LW, Kilpatrick ES, Jayagopal V, Diver MJ, Atkin SL. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxf) 2008;68:390–4.10.1111/j.1365-2265.2007.03053.xSearch in Google Scholar PubMed
12. Golbahar J, Al-Ayadhi M, Das NM, Gumaa K. Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain. Int J Womens Health 2012;4:201-206.10.2147/IJWH.S30661Search in Google Scholar PubMed PubMed Central
13. Pinola P, Piltonen TT, Puurunen J, Vanky E, Sundstrom-Poromaa I, Stener-Victorin E, Ruokonen A, Puukka K, Tapanainen JS, Morin-Papunen LC. Androgen profile through life in women with polycystic ovary syndrome: a nordic multicenter collaboration study. J Clin Endocrinol Metab 2015;100:3400–7.10.1210/jc.2015-2123Search in Google Scholar PubMed
14. Olszanecka A, Kawecka-Jaszcz K, Czarnecka D. Association of free testosterone and sex hormone binding globulin with metabolic syndrome and subclinical atherosclerosis but not blood pressure in hypertensive perimenopausal women. Arch Med Sci 2016;12:521–8.10.5114/aoms.2016.59925Search in Google Scholar PubMed PubMed Central
15. Guducu N, Kutay SS, Gormus U, Kavak ZN, Dunder I. High DHEAS/free testosterone ratio is related to better metabolic parameters in women with PCOS. Gynecol Endocrinol 2015;31:495–500.10.3109/09513590.2015.1022862Search in Google Scholar PubMed
16. Georgopoulos NA, Papadakis E, Armeni AK, Katsikis I, Roupas ND, Panidis D. Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones (Athens) 2014;13:213–21.10.1007/BF03401335Search in Google Scholar PubMed
17. Papalou O, Livadas S, Karachalios A, Tolia N, Kokkoris P, Tripolitakis K, Diamanti-Kandarakis E. White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandogenemia. Hormones (Athens) 2015;14:91–100.10.14310/horm.2002.1563Search in Google Scholar PubMed
18. Clark CM, Rudolph J, Gerber DA, Glick S, Shalita AR, Lowenstein EJ. Dermatologic manifestation of hyperandrogenism: a retrospective chart review. Skinmed 2014;12:84–8.Search in Google Scholar
19. Schmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, Lee J, Zane LT, Shinkai K. Cutaneous findings and systemic associations in women with polycystic ovary syndrome. JAMA Dermatol 2016;152:391–8.10.1001/jamadermatol.2015.4498Search in Google Scholar PubMed
20. Hong JS, Kwon HH, Park SY, Jung JY, Yoon JY, Min S, Choi YM, Suh DH. Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients. J Eur Acad Dermatol Venereol 2015;29:42–7.10.1111/jdv.12432Search in Google Scholar PubMed
21. Quinn M, Shinkai K, Pasch L, Kuzmich L, Cedars M, Huddleston H. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril 2014;101:1129–34.10.1016/j.fertnstert.2014.01.003Search in Google Scholar PubMed
22. Luque-Ramirez M, Escobar-Morreale HF. Adrenal hyperandrogenism and polycystic ovary syndrome. Curr Pharm Des 2016;22:5588–602.10.2174/1381612822666160720150625Search in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Original Articles
- Hypomagnesaemia: a modifiable risk factor of diabetic nephropathy
- The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome
- Vitamin D modulates the expression of HLA-DR and CD38 after in vitro activation of T-cells
- Hyperandrogenemia in women with polycystic ovary syndrome: prevalence, characteristics and association with body mass index
Articles in the same Issue
- Frontmatter
- Original Articles
- Hypomagnesaemia: a modifiable risk factor of diabetic nephropathy
- The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome
- Vitamin D modulates the expression of HLA-DR and CD38 after in vitro activation of T-cells
- Hyperandrogenemia in women with polycystic ovary syndrome: prevalence, characteristics and association with body mass index
